Physician profile
Ron V Kirkpatrick
NPI 1407833478
$3,238.87
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.80 · 2022: $865 · 2023: $1,534 · 2024: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.92 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.55 | 2021-2024 | |
| Astellas Pharma US INC | $380.29 | 2022-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $364.23 | 2021-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $304.44 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $208.66 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.94 | 2022-2023 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $144.95 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $141.77 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $138.06 | 2022 | |
| Gilead Sciences, INC. | $107.32 | 2022 | |
| Viiv Healthcare Company | $99.78 | 2023-2024 | Apretude, Dovato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.45 | 2022-2024 | Stiolto Respimat, Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $85.31 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $83.48 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $61.84 | 2022-2023 | Otezla, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $61.08 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $52.11 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $40.26 | 2023 | Eliquis |
| Almatica Pharma LLC | $32.45 | 2022-2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $25.35 | 2023 | Abilify Asimtufii, Rexulti |
| Biohaven Pharmaceuticals, INC. | $24.53 | 2021 | |
| Edwards Lifesciences Corporation | $18.99 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kowa Pharmaceuticals America, INC. | $17.34 | 2023 | Seglentis |
| Tolmar, INC. | $17.27 | 2023 | |
| Phathom Pharmaceuticals, INC. | $13.42 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Kirkpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.